Tun Nay Min, Oo Thein Hlaing
Division of Hematology and Oncology, The Brooklyn Hospital Center, 121 Dekalb Avenue, Brooklyn, NY 11201, USA.
Thrombosis. 2013;2013:183616. doi: 10.1155/2013/183616. Epub 2013 Feb 21.
Traditional anticoagulants, such as warfarin and enoxaparin, have several limitations, including parenteral administration, need for laboratory monitoring, and ongoing dose adjustment, which may limit optimal patient care. Newer oral anticoagulants, such as direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban), have been developed to overcome these drawbacks, and thereby improve patient care. Several of these agents have been approved for use in the prevention and treatment of venous and/or systemic thromboembolism. The objective of this paper is to provide an overview of the available clinical trial data for these new oral anticoagulants in the prevention and treatment of venous thromboembolism and a practical update for clinicians.
传统抗凝剂，如华法林和依诺肝素，有几个局限性，包括肠胃外给药、需要实验室监测以及持续调整剂量，这可能会限制对患者的最佳护理。新型口服抗凝剂，如直接凝血酶抑制剂（如达比加群酯）和直接Xa因子抑制剂（如利伐沙班、阿哌沙班和依度沙班），已被开发出来以克服这些缺点，从而改善患者护理。其中几种药物已被批准用于预防和治疗静脉和/或全身性血栓栓塞。本文的目的是概述这些新型口服抗凝剂在预防和治疗静脉血栓栓塞方面的现有临床试验数据，并为临床医生提供实用的最新信息。
